STAT+: Bristol Myers Squibb partners with China’s Hengrui Pharma on a dozen drugs

STAT PlusPharma Bristol Myers Squibb partners with China’s Hengrui Pharma on a dozen drugs The deal, worth up to $15.2 billion, is the latest case of a large pharma company looking to China to expand its pipeline Manage alerts for this article Email this article Share this article By Andrew JosephMay 12, 2026 Europe Correspondent Andrew Joseph[email protected]Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. Bristol Myers Squibb announced on Tuesday a partnership with Hengrui Pharma covering more than a dozen early-stage programs, the latest and a notably large case of a global pharmaceutical company looking to China for its next medicines.

The licensing agreement includes a $600 million upfront payment from Bristol to Hengrui, and has a potential value of up to $15.2 billion if all milestones for the included drugs are reached.Advertisement As part of the deal, Bristol will gain the rights to four Hengrui oncology and hematology drug candidates outside of mainland China, Hong Kong, and Macau. The pact also gives Hengrui the rights to commercialize four immunology drugs from Bristol in that region. And the companies will work together to advance five other drugs, with Hengrui taking the lead on the early clinical development of all the programs.

STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+. Already have an account?

Log in Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%! Request A Quote Request A Quote Savings start at 25%! 2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user View All Plans To read the rest of this story subscribe to STAT+.

Subscribe Log In drug development, Pharmaceuticals, STAT+ Submit a correction requestReprints Andrew Joseph Europe Correspondent Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. Newsletter Understand how science, health policy, and medicine shape the world every day Recommended Politics May 11, 2026 Supreme Court temporarily extends women’s access to a widely used abortion pill Pharmalot May 11, 2026 STAT Plus: Colombia wins a key court ruling over a compulsory license issued for an HIV medicine Advertisement Health May 11, 2026 STAT Plus: Trump pivots on kratom derivative 7-OH, floating approval for some forms Health Care Inc.

Newsletter May 11, 2026 STAT Plus: Medicare’s miss on Alzheimer’s drug spending Health May 11, 2026 No FDA permission, no problem: New flavored vape policy worries experts Subscriber Picks